logo
Plus   Neg
Share
Email

Myriad Genetics Reports Regulatory Approval Of BRACAnalysis In Japan

Myriad Genetics, Inc. (MYGN) announced the Japan's Ministry of Health, Labour and Welfare has approved the BRACAnalysis Diagnostic System for Hereditary Breast and Ovarian Cancer risk assessment in patients with breast cancer.

BRACAnalysis is a genetic test that identifies germline mutations in the BRCA1/2 genes. This test will assist physicians in determining which women with breast cancer have Hereditary Breast and Ovarian Cancer syndrome and qualify for additional medical management.

Myriad has an exclusive partnership with SRL Inc. to commercialize the BRACAnalysis Diagnostic System in Japan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT